1. Home
  2. ABEO vs WENN Comparison

ABEO vs WENN Comparison

Compare ABEO & WENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • WENN
  • Stock Information
  • Founded
  • ABEO 1974
  • WENN 2025
  • Country
  • ABEO United States
  • WENN United States
  • Employees
  • ABEO N/A
  • WENN N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • WENN
  • Sector
  • ABEO Health Care
  • WENN
  • Exchange
  • ABEO Nasdaq
  • WENN Nasdaq
  • Market Cap
  • ABEO 350.2M
  • WENN 380.1M
  • IPO Year
  • ABEO 1980
  • WENN 2025
  • Fundamental
  • Price
  • ABEO $5.73
  • WENN $10.16
  • Analyst Decision
  • ABEO Strong Buy
  • WENN
  • Analyst Count
  • ABEO 6
  • WENN 0
  • Target Price
  • ABEO $18.17
  • WENN N/A
  • AVG Volume (30 Days)
  • ABEO 714.3K
  • WENN 143.3K
  • Earning Date
  • ABEO 11-13-2025
  • WENN 01-01-0001
  • Dividend Yield
  • ABEO N/A
  • WENN N/A
  • EPS Growth
  • ABEO N/A
  • WENN N/A
  • EPS
  • ABEO 0.99
  • WENN N/A
  • Revenue
  • ABEO $400,000.00
  • WENN N/A
  • Revenue This Year
  • ABEO N/A
  • WENN N/A
  • Revenue Next Year
  • ABEO $324.71
  • WENN N/A
  • P/E Ratio
  • ABEO $5.80
  • WENN N/A
  • Revenue Growth
  • ABEO N/A
  • WENN N/A
  • 52 Week Low
  • ABEO $3.93
  • WENN $9.67
  • 52 Week High
  • ABEO $7.54
  • WENN $10.40
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 31.45
  • WENN N/A
  • Support Level
  • ABEO $6.53
  • WENN N/A
  • Resistance Level
  • ABEO $6.95
  • WENN N/A
  • Average True Range (ATR)
  • ABEO 0.29
  • WENN 0.00
  • MACD
  • ABEO -0.12
  • WENN 0.00
  • Stochastic Oscillator
  • ABEO 3.39
  • WENN 0.00

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

About WENN Wen Acquisition Corp Class A Ordinary Shares

Wen Acquisition Corp is a blank check company.

Share on Social Networks: